Objective: Whether platelet-lymphocyte ratio (PLR) is a prognostic factor for cancer patients treated with immunotherapy is under debate. In this study, we aimed to evaluate the relationship between PLR and survival of cancer patients treated with immune checkpoint inhibitors (ICIs).

Methods: A systematical search was performed in databases including PubMed, Embase, and the Cochrane library to retrieve potential eligible clinical studies assessing the prognosis of cancer patients with high versus low PLR after immunotherapy, from the establishment of the database to June 2019. Quality evaluation of included studies was performed, and meta-analyses with regards to overall survival (OS) and progression-free survival (PFS) were conducted using RevMan 5.3 and STATA 11.

Results: A total of 12 eligible studies with 1340 cancer patients were included. Combined results showed that elevated PLR was a negative factor affecting the efficacy of ICIs in cancer patients. Patients with high PLR had a significantly shorter OS compared to those with low PLR (hazard ratio (HR) = 2.02, 95% confidence interval (CI): 1.46 to 2.80, P < 0.0001), as well as PFS (HR = 1.74, 95%CI: 1.27 to 2.38, P = 0.0006). Similar results were observed in sensitivity analyses. Subgroup analyses revealed that the prognostic role of PLR on OS and PFS was dependent on cancer type, region, and cutoff value. For NSCLC patients, the disease stage, ICIs agent, and line of treatment may not influence the prognostic role of PLR.

Conclusion: PLR could be a routinely potential prognostic factor for ICIs. Low PLR may be associated with better survival for cancer patients when treated with immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2019.105957DOI Listing

Publication Analysis

Top Keywords

cancer patients
24
patients treated
12
platelet-lymphocyte ratio
8
treated immune
8
immune checkpoint
8
checkpoint inhibitors
8
patients high
8
low plr
8
patients
7
cancer
6

Similar Publications

Background: Solid organ transplantation (SOT) is vital for end-stage organ failure but faces challenges like organ shortage and rejection. Artificial intelligence (AI) offers potential to improve outcomes through better matching, success prediction, and automation. However, the evolution of AI in SOT research remains underexplored.

View Article and Find Full Text PDF

MYCN-amplified spinal ependymomas: a rare aggressive subtype. Illustrative cases.

J Neurosurg Case Lessons

January 2025

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Background: Spinal ependymomas are typically slow-growing tumors with a favorable prognosis. Recently, a new aggressive subtype has emerged with its own distinct histopathological and molecular features characterized by MYCN amplification. However, this subtype of spinal ependymoma is rare, and studies on its imaging characteristics are limited.

View Article and Find Full Text PDF

Hypermagnesemia- and Hyperphosphatemia-Associated Cardiac Arrest after Injection of a Novel Magnesium-Based Bone Cement in Spinal Surgery.

J Am Acad Orthop Surg Glob Res Rev

January 2025

From the Department of Orthopaedic Surgery, Singapore General Hospital, Singapore (Dr. Loh, Dr. Ling, Dr. Jiang, and Lim) and the Department of Surgical Intensive Care, Division of Anaesthesiology and Perioperative Medicine, Singapore General Hospital, Singapore (Dr. Goh).

We report a case of pulseless electrical activity (PEA) associated with profound hypermagnesemia immediately after cementation of a novel magnesium-based cement in spine surgery. During T8 to T12 posterior instrumentation and decompression laminectomy for vertebral metastasis secondary to lung cancer, a 61-year-old Chinese woman developed sudden hypotension and went into PEA immediately after injection of a novel magnesium-based cement. Intraoperative fluoroscopic imaging did not show any notable cement extravasation.

View Article and Find Full Text PDF

Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?

J Clin Oncol

January 2025

Aaron J. Scott, MD, University of Arizona Cancer Center, Tucson, AZ; Erin B. Kennedy, MHSc, American Society of Clinical Oncology, Alexandria, VA; and Sepideh Gholami, MD, MAS, Northwell Health, New Hyde Park, NY.

View Article and Find Full Text PDF

Objectives: Detection of fat content in thymic lesions is essential to differentiate thymic hyperplasia from thymic tumors. This study assesses the reliability and efficacy of "iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantization" IDEAL-IQ magnetic resonance sequence in distinguishing thymic hyperplasia from low-risk thymoma and thymic lymphoma in adulthood.

Methods: Thirty patients with thymic hyperplasia, 28 low-risk thymomas, and 13 thymic lymphomas were respectively enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!